• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Valeant focused on bringing new products to market, receives CRL pharmafile
    August 10, 2017
    It revealed that it had paid down $4.8 billion on its mountain of debt since the first quarter of 2016 and CEO, Joseph Papa, said that the company would focus on launching new products, instead of selling parts of the business, to further reduce this.
Previous page 1 2 Next page

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service